Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 23, 2007 - Late breaking data presented at the American Diabetes Association (ADA) 67th Annual Scientific Sessions showed that, when used investigationally as initial therapy, JANUVIA(TM) (sitagliptin) in combination with metformin provided significant glycemic improvement and was generally well tolerated over 54 weeks in patients with type 2 diabetes. Additional new data from investigational studies presented also showed that JANUVIA significantly improved blood sugar control in patients with type 2 diabetes when added to a sulfonylurea, glimepiride (dual combination therapy), or when added to a sulfonylurea and metformin (triple combination therapy). Additional data were presented at the meeting regarding the efficacy and safety of JANUVIA.

JANUVIA is a selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances a natural body system, called the incretin system, which helps to regulate glucose by affecting the beta cells and alpha cells in the pancreas. JANUVIA is the first and only DPP-4 inhibitor to be approved and marketed in the United States for patients with type 2 diabetes. JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus. JANUVIA is also indicated to improve glycemic control, in combination with metformin or a thiazolidinedione (TZD), in patients with type 2 diabetes when the single agent alone plus diet and exercise do not provide adequate glycemic control. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. There are no contraindications for JANUVIA.

Sitagliptin is also a component of JANUMET(TM) (sitagliptin/metformin HCl), the first and only tablet combining a DPP-4 inhibitor and metformin for the treatment of type 2 diabetes. JANUMET is indicated, as an adjunct to
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has ... (London, UK - November 16-18, 2015)" conference to their offering. ... including Columbia, Peru , Brazil ... Uruguay , Paraguay , ... , Chile This seminar can ...
(Date:9/2/2015)... -- Seeger Weiss LLP is reporting that Zimmer Holdings Inc.,s ... 2015. Since the product was approved ... NexGen knee implant surpassed FDA investigation and mandatory product ... that the product is substantially similar to a preexisting ... In 2001, Zimmer began distributing High ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... of the "Medical Device Studies: Clinical Evidence ... to their offering. This course ... involved in gathering clinical evidence required for medical ... required for all medical devices and the emphasis ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
... Potential New Approach for the Treatment of Inflammatory ... ... Million Payment from Partner GlaxoSmithKline, MOUNTAIN VIEW, Calif., May 13 ... trial of CCX354, an,orally-available, novel small molecule compound designed to specifically,target ...
... FRANCISCO, Calif., May 12 Napo,Pharmaceuticals, Inc., (LSE: ... in collaboration with QualityMetric, Inc. describing the development,of ... Health-Related,Quality of Life (HR-QoL) aspects of chronic diarrhea ... Society for Pharmacoeconomics and,Outcomes Research (ISPOR) Annual Meeting ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Napo Presents at ISPOR Meeting in Toronto 2
(Date:9/3/2015)... ... ... Mum n Me is pleased to announce the launch of its ... maximum protection from sun exposure, wind, bugs, and germs. The Mum n Me Baby ... keeping the cover securely in place. The new car seat cover is made with ...
(Date:9/3/2015)... ... September 03, 2015 , ... When looking at the types of people who have ... of two categories: those that have a weak appetite or those that have a fast ... to gain weight, CB-1 Weight Gainer gives three tips for slowing down metabolism. , The ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... announced that Bob Anders and Kelley Chapman will be joining the company’s executive ... , Anders has over 30 years’ experience in healthcare product and project ...
(Date:9/2/2015)... Basalt, Colorado (PRWEB) , ... September 03, 2015 , ... ... to its wellness services - two retreats geared towards kick-starting and inspiring wellness in ... "We love being a part of developing a whole mind-body approach to fitness - ...
(Date:9/2/2015)... ... September 03, 2015 , ... Each year, the editors of ... servants, activists, corporate executives, entrepreneurs, health care professionals, and others have had the ... the magazine to tap the National League for Nursing’s outspoken CEO, Beverly ...
Breaking Medicine News(10 mins):Health News:Mum n Me Announces New Baby Car Seat Cover 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3
... lawyers' access to a high-profile detainee at Guantanamo Bay, ... security secrets" whose revelation could "cause extremely grave damage", ... prisoners at secret CIA prisons must not be allowed ... - even to their lawyers, the Post reported.,A lawyer ...
... Researchers want doctors to be ready to handle medical problems ... it. //In the present state, what happens when a person ... get back to normal conditions for treatment in time simply ... findings from a UF study show there is little difference ...
... the trans-fat controversy for quite a while, has decided to ... oils! This is perhaps the last nail in the coffin! ... have already communicated their intention of banishing trans fats from ... Government to bring in a law that would entail manufacturers ...
... leading economic think tank has urged policymakers to ensure ... women to reduce their// economic and social vulnerability., ... disproportionately affected by HIV and AIDS get equal opportunities ... Economic Research (NCAER) in a report on 'Gender impact ...
... against time to prevent HIV, the virus that causes AIDS, ... in// the number of prostitutes and lack of safe sex ... three-year programme to encourage the use of condoms and voluntary ... UNAIDS estimates 500 HIV-infected people in Bhutan, a country of ...
... battled off the infection appear to be shielded from ... Canadian study.// ,WebMD.com said that Drug users ... British Columbia researchers for presence of Hepatitis C antibodies ... C mainly through their habit of sharing needles during ...
Cached Medicine News:Health News:Researchers explore medicine in space 2Health News:Researchers explore medicine in space 3Health News:Equal Opportunities For HIV-Positive Women Urged 2Health News:HIV/AIDS Epidemic Scare In Bhutan 2
... Solution For Your Tracheostomy Care Needs, ... features the latest components for efficient and ... task. Designed by clinicians, these latex-free trays ... patient and caregiver. All of our trays ...
... Medline Has the Right Solution For ... tracheostomy clean and care tray features the ... of this important infection control task. Designed ... the individual needs of each patient and ...
... and alternate care facilities with a ... which offer the finest in nursing ... the guidance of experienced nursing personnel, ... what is required for efficient and ...
... and alternate care facilities with a ... which offer the finest in nursing ... the guidance of experienced nursing personnel, ... what is required for efficient and ...
Medicine Products: